Basic information
- Standard SMILES
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21.Cl- InChIKey
HVRLZEKDTUEKQH-NOILCQHBSA-N- Molecular formula
- C21H24ClNO3
- Average molar mass
- 373.9 g/mol
- Monoisotopic mass
- 373.14447131
Overview
Olopatadine hydrochloride is a dibenzooxazepine.
Names & identifiers
- Preferred name
- Olopatadine Hydrochloride
- IUPAC
- 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid;hydrochloride
Names & synonyms
OLOPATADINE HYDROCHLORIDE140462-76-6OLOPATADINE HClPatadayAllelockPatanasePazeoALO4943AKW4679DTXSID0046486KW-4679ALO-4943A
Show more names
Olopatadine (as hydrochloride)2XG66W44KFDTXCID8026486Dibenz(b,e)oxepin-2-acetic acid, 11-(3-(dimethylamino)propylidene)-6,11-dihydro-, hydrochloride, (Z)-RYALTRIS COMPONENT OLOPATADINE HYDROCHLORIDERetaine AllergyOnce Daily ReliefRefChem:56800
Database identifiers
- CAS
140462-76-6- PubChem CID
- 5282402
- DTXSID
DTXSID0046486- ChEMBL
CHEMBL1719- ChEBI
CHEBI:31933- UNII
- 2XG66W44KF
- EC Number
- 604-185-4
Properties
Computed structural properties
- Topological polar surface area
- 49.8 Ų
- Hydrogen bond donors
- 2
- Hydrogen bond acceptors
- 4
- Rotatable bonds
- 5
- Heavy atoms
- 26
- Formal charge
- 0
- Complexity
- 488
Experimental & physicochemical properties
Human Drugs
FDA approved drugs -> Active ingredient
EMA approved medicines: Human medicine
FDA approved drugs -> Active ingredient
Safety & regulation
GHS classification
GHS Classification
This chemical does not meet GHS hazard criteria for 4.3% (2 of 47) of reports.
Danger
H301 (87.2%): Toxic if swallowed [Danger Acute toxicity, oral]
P264, P270, P273, P301+P316, P321, P330, P391, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 47 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Hazard information
Hazard Classes and CategoriesAcute Tox. 3 (87.2%)
Toxicology
Exposure RoutesOphthalmic use of olopatadine usually does not produce measurable plasma concentrations.
Toxicity Summary
Olopatadine is a selective histamine H1 antagonist that binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors.
Signs and Symptoms
Its side effects may include headaches (7% of occurrence) burning and stinging (5%), dry eye, foreign body sensation, hyperemia, keratitis, lid edema, pruritus, asthenia, cold syndrome, pharyngitis, rhinitis, sinusitis, and taste perversion. [Wikipedia]
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Chemistry & industry
Pharmacology
Metabolism/MetabolitesThe mono-desmethyl and the N-oxide metabolites have been detected at low concentrations in the urine.
Route of Elimination: Elimination was predominantly through renal excretion.
Half Life: 3 hours
FDA Pharmacological Classification
OLOPATADINE HCL
Decreased Histamine Release [PE]; Mast Cell Stabilizer [EPC]; Histamine-1 Receptor Antagonist [EPC]; Histamine-1 Receptor Inhibitor [EPC]; Histamine H1 Receptor Antagonists [MoA]
OLOPATADINE HYDROCHLORIDE
Mast Cell Stabilizer [EPC]; Decreased Histamine Release [PE]; Histamine-1 Receptor Antagonist [EPC]; Histamine H1 Receptor Antagonists [MoA]; Histamine-1 Receptor Inhibitor [EPC]
OLOPATADINE HYDROCHLORIDE OPHTHALMIC
Decreased Histamine Release [PE]; Mast Cell Stabilizer [EPC]; Histamine-1 Receptor Antagonist [EPC]; Histamine-1 Receptor Inhibitor [EPC]; Histamine H1 Receptor Antagonists [MoA]
MeSH Pharmacological Classification
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)
A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment.
Uses & manufacturing
UsesFor the treatment of ocular itching associated with allergic conjunctivitis. Used as an antihistamine. [Wikipedia]
Related reactions
2 records
Linked notes
Loading…